- Home
- KRKR vs APLM Comparison
KRKR vs APLM Comparison
Compare KRKR & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRKR
- APLM
- Stock Information
- Founded
- KRKR 2010
- APLM 2016
- Country
- KRKR China
- APLM United States
- Employees
- KRKR N/A
- APLM N/A
- Industry
- KRKR Business Services
- APLM Blank Checks
- Sector
- KRKR Consumer Discretionary
- APLM Finance
- Exchange
- KRKR Nasdaq
- APLM Nasdaq
- Market Cap
- KRKR 10.4M
- APLM 12.3M
- IPO Year
- KRKR 2019
- APLM N/A
- Fundamental
- Price
- KRKR $4.15
- APLM $7.02
- Analyst Decision
- KRKR
- APLM Strong Buy
- Analyst Count
- KRKR 0
- APLM 2
- Target Price
- KRKR N/A
- APLM $425.00
- AVG Volume (30 Days)
- KRKR 1.3M
- APLM 7.4K
- Earning Date
- KRKR 04-17-2025
- APLM 03-04-2025
- Dividend Yield
- KRKR N/A
- APLM N/A
- EPS Growth
- KRKR N/A
- APLM N/A
- EPS
- KRKR N/A
- APLM N/A
- Revenue
- KRKR $41,654,350.00
- APLM $2,101,000.00
- Revenue This Year
- KRKR $45.99
- APLM N/A
- Revenue Next Year
- KRKR $31.46
- APLM N/A
- P/E Ratio
- KRKR N/A
- APLM N/A
- Revenue Growth
- KRKR N/A
- APLM 70.54
- 52 Week Low
- KRKR $2.76
- APLM $6.38
- 52 Week High
- KRKR $12.99
- APLM $80.50
- Technical
- Relative Strength Index (RSI)
- KRKR 46.65
- APLM 37.88
- Support Level
- KRKR $3.30
- APLM $6.70
- Resistance Level
- KRKR $6.20
- APLM $7.60
- Average True Range (ATR)
- KRKR 1.03
- APLM 0.70
- MACD
- KRKR -0.24
- APLM -0.03
- Stochastic Oscillator
- KRKR 22.84
- APLM 22.30
About KRKR 36Kr Holdings Inc.
36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in PRC.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.